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Background: The administration of certain cannabinoids provides neuroprotection in models of neurodegenerative
diseases by acting through various cellular and molecular mechanisms. Many cannabinoid actions in the nervous
system are mediated by CB1 receptors, which can elicit psychotropic effects, but other targets devoid of psychotropic
activity, including CB2 and nuclear PPARγ receptors, can also be the target of specific cannabinoids.
Methods: We investigated the pro-neurogenic potential of the synthetic cannabigerol derivative, VCE-003.2, in striatal
neurodegeneration by using adeno-associated viral expression of mutant huntingtin in vivo and mouse embryonic
stem cell differentiation in vitro.
Results: Oral administration of VCE-003.2 protected striatal medium spiny neurons from mutant huntingtin-induced
damage, attenuated neuroinflammation and improved motor performance. VCE-003.2 bioavailability was characterized
and the potential undesired side effects were evaluated by analyzing hepatotoxicity after chronic treatment. VCE-003.2
promoted subventricular zone progenitor mobilization, increased doublecortin-positive migrating neuroblasts towards
the injured area, and enhanced effective neurogenesis. Moreover, we demonstrated the proneurogenic activity of
VCE-003.2 in embryonic stem cells. VCE-003.2 was able to increase neuroblast formation and striatal-like CTIP2-
mediated neurogenesis.
Conclusions: The cannabigerol derivative VCE-003.2 improves subventricular zone-derived neurogenesis in
response to mutant huntingtin-induced neurodegeneration, and is neuroprotective by oral administration.
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Huntington’s disease (HD) is a monogenic neurodegenera-
tive disease produced by the expression of mutant hun-
tingtin (htt) protein with expanded glutamine repeats in
the N-terminal portion of the protein [1]. Mutant htt ex-
pression induces striatal atrophy and medium spiny
neuron (MSN) death, which is responsible for the charac-
teristic motor symptoms of the disease. The length of the
polyglutamine tract expansion in the htt gene, higher than
40 repeats, is closely associated with disease onset. Hence,
although HD neurodegeneration occurs in adult brain,
mutant htt expression is also known to interfere with nor-
mal neurodevelopment at several levels. Mutant hunting-
tin interferes with the activity of various transcription
factors (GSX2+, ASCL1+, ISLT1+, NKX2.1) that are es-
sential in controlling cortical and striatal neurogenesis [2,
3]. Among others, mutant huntingtin decreases NeuroD1
activity, a transcription factor that acts as a major conflu-
ence node of different neurodevelopmental gene pathways
[3]. Mutant huntingtin also alters the mode of division of
subventricular zone (SVZ) progenitors by influencing mi-
totic spindle orientation, that in turn controls asymmetric
cell division and neurogenesis [4]. Moreover, mutant hun-
tingtin expression interferes with projection neuron mi-
gration as normal huntingtin regulates Rab11-mediated
N-cadherin trafficking [5].
Certain cannabinoids, the main active compounds of
Cannabis sativa, and their endogenous counterparts
2-arachidonoylglycerol and anandamide exert symptomatic
relief in various neurodegenerative and neuroinflammatory
conditions [6]. Neuroprotection in mouse HD models as
induced by Δ9-tetrahydrocannabinol (THC), the most
abundant bioactive compound of Cannabis sativa, occurs
at least in part in a cell-autonomous manner via the CB1
receptor [7]. Unfortunately, considering that CB1 receptor
levels notably diminish at early stages of HD [8–10], and
that CB1 receptor agonists produce undesired psychoactive
effects [11], the development of clinical treatments based
on CB1-receptor acting cannabinoids constitutes an ex-
tremely complicated task. Hence, investigating the potential
use of cannabinoids other than THC, with different
pharmacological profiles, constitutes an interesting research
area for the development of new candidate molecules with
reduced unwanted actions. Cannabigerol (CBG) is a
non-psychoactive cannabinoid that has been tested as a
candidate molecule for pharmacological therapies in HD
experimental models [12]. CBG via the nuclear receptor
peroxisome proliferator-activated receptor-γ (PPARγ) alle-
viates motor symptoms, neuroinflammation and neurode-
generation in murine models of HD based on either striatal
neurotoxicity (3-nitropropionic acid injection model) or
transgenic expression of human mutant huntingtin exon 1
(R6/2 model) [12]. Of interest, thiazolidinedione-induced
PPARγ activation is neuroprotective against mutanthuntingtin-induced cell death and reduce huntingtin aggre-
gates in the brain [13]. In order to improve the pharmaco-
logical profile of CBG, chemical modifications were
introduced, leading to the CBG quinone derivatives
VCE-003 and VCE-003.2 [14, 15]. VCE-003.2
([2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydrox-
y-5-pentyl-(1,4) benzoquinone]), an aminoquinone deriva-
tive of CBG, improves the pharmacological profile of
VCE-003 by eliminating the characteristic side effects of
potent PPARγ activators. Fundamentally, VCE-003.2 is
neuroprotective in the quinolinic acid-administration
model of HD and increases neural progenitor survival [14].
In the present study, we evaluated the neuroprotective
efficacy of oral VCE-003.2 administration. Noteworthy,
oral VCE-003.2 was neuroprotective against mutant
huntingtin-induced damage, and also improved
SVZ-derived neurogenesis. Overall, these findings pro-
vide further support to the neuroprotective and anti-
inflammatory activities of VCE-003.2, and suggests its
potential as a disease-modifying agent, considering its
ability to improve the endogenous neurogenic response.
Methods
Cell culture and reagents
All reagents, unless indicated, were from Sigma-Aldrich
(St. Louis, MO, USA). The synthesis and structure of
VCE-003.2 were previously described [14, 15]. Mouse
embryonic teratocarcinoma P19 were cultured in
high-glucose DMEM (Invitrogen) supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin.
P19 cells were plated in 24-well plates and transfected
with Lipofectamine 2000 reagent according to the manu-
facture’s protocol (Invitrogen). Twenty-four hours post
transfection, cells were collected for RNA extraction or
luciferase assay determinations. P19 neurosphere forma-
tion assay was performed using dissociated P19 cells cul-
tured in high-glucose DMEM (Invitrogen) supplemented
with 5% of fetal bovine serum and 0. 5 μM retinoic acid.
Twenty-four hours later the mean neurosphere size was
quantified. Luciferase construct with the MAR sequence
A4 of the Ctip2 promoter was kindly provided (R.
Grosschedl, Max-Planck-Institute of Immunobiology
and Epigenetics, Freiburg, Germany).
Mouse embryonic stem cell differentiation
R1 mouse embryonic stem (mES) cell line was grown on
gelatin 0.1%, in Knockout DMEM supplemented with
20% Knockout Serum Replacement, 1000 Uml-1 of LIF,
0.1 mM of non-essential amino acids, 2 mM ultragluta-
mine, 50 Uml-1 of penicillin and streptomycin and 0.1
mM of 2-mercaptoethanol. Cells were then differentiated
at low density in Defined Default Medium (DDM) con-
taining DMEM/F12 + GlutaMAX supplemented with N2
supplement (1×), 5 mM of Hepes Buffer, 0.1 mM of
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2.5 mgml-1 of AlbuMax-I, 30 mM of D-Glucose, 0.1
mM of non-essential amino acids, 0.1 mM of
2-mercaptoethanol, 50 Uml-1 of penicillin and strepto-
mycin for 12 days. The cells were then plated on polyly-
sine/laminin-coated dishes in 50% DDM and 50%
Neurobasal/B27 containing Neurobasal supplemented
with B27 (1×), 2 mM of Ultraglutamine and 50 Uml-1 of
penicillin and streptomycin for 9 days.
Luciferase transcriptional assays
To study CTIP2 transcriptional activity P19 cells were
seeded in 24-well plates and transiently co-transfected
with the luciferase reporter vector MARS-A4-luc [16]
using Roti-Fect (Carl Roth, Karlsruhe, Germany) follow-
ing the manufacturer’s instructions. To correct for trans-
fection efficacy, 100 ng Renilla luciferase (pRL-CMV)
was also cotransfected. After stimulation, the luciferase
activities were quantified using Dual-Luciferase Assay
(Promega, Madison, WI, USA).
Mutant huntingtin-induced neurodegeneration
Male C57BL/6 N mice (10 weeks old) were housed under
standard conditions (12-h light/dark cycle) in groups with
access to food and water ad libitum. All experiments were
performed in accordance with European Union guidelines
and approved by the Animal Research Ethics Committee
of Complutense and Córdoba University. Procedures were
designed to minimize the number of animals used and
their suffering. Constructs expressing CFP-tagged human
huntingtin exon 1 harboring a pathogenic polyQ tract of
94 CAG repeats or a normal, non-pathogenic polyQ tract
of 16 CAG repeats (kindly provided by Dr. José J. Lucas,
Severo Ochoa Molecular Biology Center, Madrid, Spain)
were employed using an AAV1/AAV2 mixed serotype,
generated by polyethyleneimine transfection of HEK293TFig. 1 Experimental design for pharmacological manipulation and characterizat
viral expression of mutant huntingtin exon1cells and subsequent purification in iodixanol gradient.
Vectors were injected stereotactically (in 3 μl PBS) into
the dorsal striatum in a bilateral manner at coordinates
(mm to bregma): antero-posterior + 0.5, lateral ±2.5,
dorso-ventral − 3.5 as previously described [17].
VCE-003.2 (10mg/kg) or vehicle (sesame oil) were orally
administered once daily (Fig. 1), and for neurogenesis ex-
periments BrdU (100mg/kg) was administered i.p. twice
daily on the first week after viral injection. RotaRod test
was conducted prior to drug injections to avoid acute ef-
fects of the compounds under investigation. RotaRod
started at 4 rpm, with an acceleration rate of 6 rpm/min
until either maximum speed is reached or the mouse falls
from the apparatus. Maximum time assay was 10min.
Basal RotaRod performance was determined 6 days prior
to striatal injury in 3 consecutive days with 3 trials/day
(30min of rest between each trial), and groups with
equivalent motor function were assigned. RotaRod test
was performed during 3 consecutive days prior to sacrifice
and plasma was obtained for peripheral biomarker ana-
lyses. All experiments included a minimum of 6 mice per
condition. The precise number of animals analyzed in
each experiment is indicated in the corresponding figure
legends.
Gene expression
Total RNA was isolated from striate using the Qiagen
RNeasy Lipid kit (Qiagen, Germany). Total RNA (1 μg)
was retrotranscribed using the iScript cDNA Synthesis
Kit and the cDNA analyzed by real-time PCR using the
iQTM SYBR Green Supermix and a CFX96 Real-time
PCR Detection System (Bio-Rad; Hercules, CA, USA).
The HPRT gene was used to standardize mRNA expres-
sion in each sample. Gene expression was quantified
using the 2-ΔΔCt method and the percentage of relative
expression against controls (untreated cells or mice) wasion of in vivo model of Huntington’s disease based on adeno-associated
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forward: 5’GAACAACGATGATGCACTTGC3’; reverse:
5’TCCAGGTAGCTATGGTACTCC3’; TNFα; forward:
5’AGAGGCACTCCC CCAAAAGA-3; reverse: CGAT
CACCCCGAAGTTCCCATT.Pharmacokinetics
Six-week old male Sprague Dawley rats (Janvier Labs,
France) were located in the rodent area of Eurofins
ADME Bioanalyses (Vergèze, France) and housed under
standard conditions (12-h light/dark cycle) in groups
with access to food and water ad libitum. Each animal
was identified by an ear tag and examined for general
health and welfare. Process, treatment and euthanasia
were conducted according to the current procedures in
use at Eurofins ADME Bioanalyses. Animals were
treated with a single intravenous bolus of VCE-003.2
(10 mg/Kg in DMSO) or with oral VCE-003.2 (50 mg/Kg
in sesame oil). At the prescribed times, blood (0.5 ml)
was collected using a capillary tube and plasma frozen at
− 20 °C until analysis. After 24 h, the animals were anes-
thetized and perfused with 20 mL of saline solution dir-
ectly into the heart to extract the maximal blood sample
from the brain. Plasma samples (100 μl) were mixed with
300 μl of acetonitrile and after protein precipitation, ana-
lysis of VCE-003.2 content was performed using
LC-MS/MS (3 animals per each time point). For brain
samples, the tissues were homogenized with an
Ultra-turrax® using UHQ water (1/1, w/w). 100 μl of
each homogenate was mixed with 300 μl of acetonitrile
and the mixture centrifuged for 5 min at 25,000 g. Brain
homogenate supernatants were directly measured by
LC-MS/MS. Previous studies have shown that there are
not significant differences between mice and rats in the
main pharmacokinetic parameters of different cannabi-
noids, including CBG [18]. As the dose used here was
different between i.v. and oral routes of administration,
bioavailability was calculated taking into account the
dose as follows: [AUCt (oral)/dose (oral)]/[AUCt(i.v.)/
dose(i.v.)].Proteome array
Plasma samples from wild-type and mutant huntingtin-
expressing C57BL/6 N mice were pooled (n = 6 animals
per group) and analyzed for cytokine and adipokine ex-
pression. The Proteome Profiler Mouse XL Cytokine
Array and the Proteome Profiler Mouse Adipokine
Array (R&D Systems) were used according to the manu-
facturer’s protocols to obtain protein expression profiles
using 100 μl plasma samples. Spot density was deter-
mined using Quick Spots image analysis software (R&D
Systems).Immunofluorescence and confocal microscopy
Free floating coronal brain slices (30 μm) were processed
as previously described [17]. In brief, after blocking with
10% goat serum, brain sections were incubated with the
indicated primary antibodies followed by secondary anti-
body incubation (2 h at room temperature). The appro-
priate mouse, rat and rabbit highly cross-adsorbed
AlexaFluor 488, AlexaFluor 594 and AlexaFluor 647 sec-
ondary antibodies (1:500; Molecular Probes, Leyden, The
Netherlands) were used. Samples were subsequently in-
cubated with DAPI (1:5000, Roche) for 10 min, washed
with PBS and mounted in Mowiol. All immunofluores-
cence data were obtained in a blinded manner by inde-
pendent observers in a minimum of 6 correlative slices,
from 1-in-10 series located between − 0.4 to + 1.6 mm to
bregma. The lateral SVZ zone was delineated by using
DAPI-counterstained cell nuclei, and analyses were
performed in the upper dorsal tier, in which
positively-labelled cells and immunoreactivity were
quantified not beyond 100 μm of the SVZ. Confocal
fluorescence images were acquired by using LAS-X soft-
ware (Wetzlar, Germany) and SP8 microscope with 2
passes by Kalman filter, a 1024X1024 collection box, and
pinhole AU 1. Double-labelled positive cells (GFAP/
Ki-67 and BrdU/NeuN cells) were counted at a magnifi-
cation of 40×. Cells were quantified within a 20 × 20 μm
counting frame, which randomly sampled within a
122.8 × 68.9 μm counting grid. Cells that contacted the
lateral or upper exclusion plane were excluded. The total
number of cells counted was divided by the number of
sampled counting frames and multiplied by its size to
obtain the density of positive cells. Co-localization was
confirmed by orthogonal projection of 18 z-stack files
(1-μm each), and data were expressed as cells/mm2.
Neurodegeneration and glial activation was determined
by dopamine- and cAMP-regulated phosphoprotein of
32 kDa mouse anti-DARPP32 (1:500 BD Transduction
Laboratories, Lexington, KY), rabbit anti-Iba-1 (1:500
Wako Pure Chemical, Osaka, Japan) and mouse
anti-GFAP-Cy3 (1:500 Sigma, St. Louis, MO) immuno-
staining, and quantified with Image-J software designed by
the National Institutes of Health (NIH; Bethesda, MD,
USA). Neurogenesis and SVZ-progenitor mobilization
were characterized by immunofluorescence with rat
anti-CTIP2 antibodies (1:500 Abcam, Cambridge, United
Kingdom). Rabbit anti-Doublecortin (1:1000 from
Abcam), rat anti-BrdU (1:250 from Abcam) and mouse
anti-NeuN (1:500 from Chemicon) antibodies, or rabbit
anti-GFAP and rabbit anti-Ki67 (1:400 from Invitrogen
and 1:500 from ThermoScientific).
Statistical analysis
In vitro data are expressed as mean ± S.D. and in vivo re-
sults are represented as mean ± SEM. Data were subjected
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ences were analyzed by one-way ANOVA followed by
Tukey post hoc test. P < 0.05 was considered significant.
Statistical analysis was performed using GraphPad Prism
version 5.01 and is shown in figure legends. Images were
analyzed and quantified using the ImageJ.
Results
VCE-003.2 exerts a pro-neurogenic effect in vitro
To investigate the pro-neurogenic potential of VCE-003.2
we analyzed its influence in ES-neuronal differentiation.
The R1 line of mouse ES cells was treated with VCE-003.2
during neural differentiation for 21 days and we assessed
CTIP2-positive striatal MSN differentiation [19]. Im-
munofluorescence quantification revealed that VCE-003.2
increased the number of CTIP2-positive cells as well as
doublecortin immunoreactivity (Fig. 2a-b). Next, using
neuralized mouse embryonic teratocarcinoma P19 cells,
we performed CTIP2 transcriptional activity assays by
transfecting a luciferase reporter construct (A4-Mar) cor-
responding to one of the regulatory MARS sequences of
the CTIP2 promoter. VCE-003.2 promoted neuronal-like
differentiation as revealed by CTIP2 reporter activation
(Fig. 2c). Furthermore, using a P19 neurosphere formation
assay, VCE-003.2 generated larger neurospheres than
vehicle-treated cells (367.90 ± 15.20 μm and 268.70 ±
9.20 μm, respectively; Fig. 2d). These results support a
pro-neurogenic action of VCE-003.2 on neural stem cell
differentiation.
Pharmacokinetics and bioavailability of VCE-003.2
As VCE-003.2 was previously shown to exert a neuro-
protective action in preclinical HD models, and consid-
ering its pro-neurogenic profile, we evaluated the
pathophysiological impact and potential therapeutic
value of VCE-003.2 after oral administration. Pharmaco-
kinetic analyses were performed in rats after oral admin-
istration of VCE-003.2 (50 mg/kg) dissolved in sesame
oil. Plasma VCE-003.2 levels peaked at 8 h (Tmax) and
then slowly declined to basal levels. Oral VCE-003.2 re-
sulted in 13.8% bioavailability and after 24 h the concen-
tration of the compound in the brain was similar upon
oral or i.v. treatment (Table 1). We also investigated
some critical ADME/Tox parameters. By using human
liver microsomes we found that VCE-003.2 undergoes a
rapid intrinsic clearance in vitro, which was similar to
the parental compound CBG (Additional file 1). More-
over, VCE-003.2 did not inhibit significantly the activity
of relevant cytochrome P450 isoforms (Additional file 2).
We also determined the potential hepatotoxicity of
chronic VCE-003.2 administration by hematoxylin-eosin
staining. VCE-003.2- and vehicle-treated mouse-derived
livers did not show any evidence of fibrosis, steatosis,
vacuolization, ballooning or inflammation (data notshown). In addition, VCE-003.2 administration did not
inhibit hERG channel activity, suggesting a potential lack
of cardiotoxicity (Additional file 3), and it was not geno-
toxic as assessed by AMES assays (Additional file 4). We
also determined the impact of VCE-003.2 administration
on peripheral biomarkers by quantifying the levels of cy-
tokines and other soluble mediators. Viral infection lead
to changes in various neuroinflammation biomarkers,
notably C-reactive protein and pentraxins 2, 3 were in-
creased by htt94Q and these changes were reverted by
VCE-003.2 treatment (Additional file 5). These data in-
dicate that mutant huntingtin induces a process of neu-
roinflammation that results in the release of soluble
factors that can be quantified in plasma and normalized
by VCE-003.2 oral administration.
Oral administration of VCE-003.2 attenuates
neuroinflammation and is neuroprotective in a viral
model of mutant huntingtin expression
To evaluate the neuroprotective profile of oral
VCE-003.2 administration, a viral model of HD was
employed [20] in which wild-type mice were subjected
to bilateral intrastriatal injection of adeno-associated
virus (AAV) expressing either exon 1 of human patho-
genic huntingtin with a polyQ tract of 94 CAG repeats,
or a normal, non-pathogenic huntingtin with a polyQ
tract of 16 CAG repeats (AAV-htt16Q and AAV-htt94Q,
respectively), and treated with VCE-003.2 (10 mg/kg/
day). Whereas expression of (exon1)-huntingtin-16Q
during 14 days did not affect motor coordination, mutant
huntingtin-94Q decreased RotaRod latency to fall (Fig. 3a).
Motor impairment in htt94Q mice was accompanied by
profound activation of microglial cells, as evidenced by Iba1
confocal immunofluorescence, in the area surrounding the
infection site (Fig. 3b). Mice treated with VCE-003.2 per-
formed better in the RotaRod test than their vehicle-treated
AAV-htt94Q counterparts, and showed reduced microglial
activation (Fig. 3a-b). Furthermore, VCE-003.2 admin-
istration prevented htt94Q-induced MSN degeneration
as evidenced by DARPP-32 and NeuN immunofluor-
escence (Fig. 4a-b). These results are in line with pre-
vious findings on the neuroprotective ability of
VCE-003.2 in toxin-based models of neurodegenera-
tion [14, 21] and expand its potential clinical profile
since oral administration was as effective as i.p. delivery.
Likewise, oral VCE-003.2 administration was also neuro-
protective and anti-inflammatory in the 3-NP model of
striatal neurodegeneration (Additional file 6).
Oral administration of VCE-003.2 promotes striatal
neurogenesis
The neuroprotective action of oral VCE-003.2 and its
pro-neurogenic impact in vitro prompted us to investi-
gate if this compound could contribute to striatal
ab
c d
Fig. 2 VCE-003.2 exerts a pro-neurogenic effect in vitro. a-b Mouse embryonic stem cells (R1 line) were treated with Vehicle, VCE-003.2 (500 nM)
during neural differentiation for 21 days. Representative immunofluorescence images and quantification of CTIP2- and doublecortin-positive cells
is shown (n = 3). c Luciferase reporter assay of the A4-MARS sequence of the CTIP2 locus was performed 24 h after P19 cell transfection under
neuronal differentiation conditions and subject to pharmacological regulation as above. d P19 neurosphere formation assay was performed by
culturing the cells for 24 h in the presence of Vehicle or VCE-003.2. Statistics: Unpaired t-test vs Vehicle a * p < 0.05; t = 2.82; df = 4; 95% Confidence
interval (CI) = 0.3149 to 36.85; R2 = 0.66. b * p < 0.05; t = 2.91; df = 4; 95% CI = 0.02 to 1.03; R2 = 0.67. c * p < 0.05; t = 2.87; df = 5; 95% CI = 0.09 to 1.72;
R2 = 0.62. d ** < 0.01 t = 5.91; df = 362; 95% CI = 66.20 to 132.20; R2 = 0.08. Scale bar, 50 μm
Table 1 Pharmacokinetic parameters of VCE-003.2. Pharmacokinetic parameters of VCE-003.2 in plasma following a single intravenous
(i.v.) (10 mg/kg) and oral (50 mg/kg) dose in Sprague Dawley rats
Compound Route Cmax (ng/mL) Tmax (h) AUCt ng/mL*h) Bioavailability Brain Concentration (24 h) (ng/mL)
VCE-003.2 IV 83160 0.08 475094.96 93.7 ± 37.7
VCE-003.2 ORAL 20266.67 8 327154.14 13.77% 86.8 ± 34.0
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Fig. 3 Oral administration of VCE-003.2 attenuates microglial activation and motor impairment induced by mutant-huntingtin expression. Wild
type C57Bl/6 N mice were injected bilaterally with mutant huntingtin expressing AAV-htt94Q and AAV-htt16Q as control. VCE-003.2 or vehicle
were administered orally daily (10 mg/kg) and mice analyzed at 2 after lesion. a Motor function was assessed in the RotaRod test and mean
latency to fold quantified. b Representative confocal microscopy images of huntingtin-CFP and immunoreactivity with an antibody for microglia
(Iba1). Iba1 immunoreactivity was quantified in the indicated experimental groups. AAV-htt16Q Vehicle and VCE-003.2 (n = 3 and 6, respectively),
AAV-htt94Q Vehicle and VCE-003.2 (n = 3 and 5, respectively). Statistics: One-way ANOVA. a F = 5.94; R2 = 0.29. **p < 0.01; q = 4.88 AAV-htt16Q Veh
vs. Mut-htt94q Veh and #p < 0.05; q = 3.90 vs AAV-htt94Q Veh vs. AAV-htt94Q VCE-003.2. b F = 5.87; R2 = 0.91. #p < 0.05; q = 5.32 vs AAV-htt16Q
VCE-003.2 vs. AAV-htt94Q Veh and ##p < 0.01; q = 3.49 vs AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh. **p < 0.01; q = 9.30 AAV-htt94Q Veh
vs. AAV-htt16Q Veh. Scale bar, 100 μm
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genesis. We analyzed the SVZ neural stem cell popula-
tion, identified as double-labelled GFAP/Ki-67 cells,
which represents the radial glia type B cell compartment.
VCE-003.2 increased the number of proliferating
GFAP-positive cells in AAV-htt94Q-injected mice, indi-
cating its positive impact on NSC mobilization (Fig. 5).
Next, SVZ-derived neural progenitors were identified by
immunofluorescence against Ascl1 (a transcription fac-
tor characteristic of the transit amplifying progenitor
subpopulation). Mutant huntingtin expression induced
an increase in Ascl1+ cell number, and VCE-003.2 ad-
ministration further promoted Ascl1-positive cell expan-
sion in AAV-htt94Q-mice (Fig. 6). To determine the
impact of VCE-003.2 on striatal neurogenesis we next
evaluated doublecortin-positive neuroblasts after 30 days
of AAV-mediated huntingtin expression and daily
VCE-003.2 administration. AAV-htt94Q-induced injuryresulted in a slight increase in neuroblast formation
(Fig. 7a) and effective neurogenesis (BrdU+NeuN+ cells)
(Fig. 7b) as compared to AAV-htt16Q. Oral administra-
tion of VCE-003.2 was effective in promoting neurogen-
esis in AAV-htt16Q- and AAV-htt94Q-treated mice,
both determined as increased doublecortin-expressing
cells and double-positive NeuN/BrdU neurons (Fig.
7a-b). Hence, oral VCE-003.2 administration is able to
restore striatal neurogenesis affected by mutant hunting-
tin expression.
Discussion
VCE-003.2 is an aminoquinone derivative of CBG that
has been designated by the FDA as an orphan drug for
HD treatment (www.accessdata.fda.gov/scripts/opdlist-
ing/oopd/detailedIndex.cfm?cfgridkey=623717). In the
present study, we demonstrate the pro-neurogenic activ-
ity of this cannabinoid derivative in a preclinical model
ab
Fig. 4 Oral administration of VCE-003.2 is neuroprotective from mutant-huntingtin-induced neurodegeneration. Wild type mice were injected
bilaterally with mutant huntingtin expressing AAV-htt94Q (mtHtt) and AAV-htt16Q (wtHtt) as control. VCE-003.2 or vehicle were administered
orally daily (10 mg/kg) and mice analyzed 30 days after lesion. Confocal microscopy characterization of huntingtin-CFP and using an antibody for
the MSN marker DARPP32. Quantification of MSN survival after lesion for the indicated experimental groups. AAV-htt16Q (Vehicle and VCE-003.2,
n = 5 each) and AAV-htt94Q (Vehicle and VCE-003.2, n = 7 each). Statistics: One-way ANOVA. a F = 31.56; R2 = 0.80. ##p < 0.01; q = 5.28 AAV-
htt94Q VCE-003.2 vs. AAV-htt94Q Veh. **p < 0.01; q = 10.63 vs AAV-htt94Q Veh vs. AAV-htt94Q Veh vs. AAV-htt16Q Veh and **p < 0.01; q = 5.56 vs
AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. b F = 27.15; R2 = 0.78. ##p < 0.01; q = 10.74 AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh and **p < 0.01;
q = 10.85 vs AAV-htt94Q Veh vs. AAV-htt16Q Veh. Scale bar, 100 μm
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ministration of VCE-003.2 exerted an anti-inflammatory
and neuroprotective action in a HD experimental model.
In addition, VCE-003.2 was able to augment mutant
huntingtin-induced SVZ-derived neurogenesis, thus favor-
ing neural stem cell mobilization (double-labelled GFAP+/
Ki-67+ and Ascl1+ cells), neuronal differentiation (double-
cortin+ cells) and effective neurogenesis (double-labelled
Brdu+/NeuN+ cells). In agreement with previous studies,
mutant huntingtin expression induced a pro-neurogenic
response that was evident by the trend towards increased
Ascl1+, Dcx+ and double-labelled BrdU+/NeuN+ cells. The
molecular signals and mechanisms underlying injury-
induced neurogenesis are diverse, and numerous thera-
peutic approaches aim to promote this endogenous
process strategy [22]. Hence, the results obtained in this
study support that striatal neurogenesis is improved
by oral VCE-003.2 administration. This new mechan-
ism of action of VCE-003.2 is relevant when consider-
ing its potential clinical applications, as it suggeststhat this molecule could constitute a disease-modifying
drug rather than merely symptom-palliative. It is worth
noting that the preclinical model of HD employed in this
study is based on the expression of exon 1 of either
mutant huntingtin or normal, non-pathogenic hun-
tingtin. The validity of this approach for mechanistic
and pharmacological investigations is demonstrated by
the high number of studies using it [23]. However,
improved animal models, for example based on the
expression of full-length huntingtin, are likely to pro-
vide novel insights of additional aspects of HD.
The use of plant derived-cannabinoid ligands has been
proposed to exert symptomatic relief of motor symp-
toms in neurodegenerative diseases, including
HD-associated dystonia and chorea, levodopa-induced
dyskinesia and tremor in Parkinson’s disease, and mul-
tiple sclerosis-associated spasticity [6, 24]. Despite the
great interest in the therapeutic potential of cannabi-
noids in neurodegenerative diseases, the undesired
side-effects of CB1 receptor agonists significantly limit
aFig. 5 Subventricular zone neural progenitor mobilization is increased by oral administration of VCE-003.2. Mice were analyzed 4 weeks after
lesion induced by AAV-htt16Q and AAV-htt94Q bilateral injection and daily treatment with vehicle or VCE-003.2 (10 mg/kg). Confocal microscopy
characterization of the SVZ was performed with GFAP, htt and Ki-67-specific antibodies in the indicated experimental groups. Proliferating SVZ-
neural stem cells were quantified based on GFAP and Ki-67 immunofluorescence colocalization. AAV-htt16Q (Veh and VCE-003.2, n = 7 and 6,
respectively) and AAV-htt94Q (Veh and VCE-003.2, n = 7 and 8, respectively). Statistics: One-way ANOVA. F = 5.78; R2 = 0.42. ##p < 0.01; q = 5.29
AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh. Scale bar, 100 μm
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gression presynaptic CB1 receptor levels decline very
early, even at presymptomatic stages [7, 9, 10]. Hence,
despite the fact that corticostriatal projections preserveCB1 receptor expression [17], the use of CB1 agonists
alone may have a limited therapeutic window, and the
development of new cannabinoid-derived molecules act-
ing via different signaling mechanisms and with reduced
Fig. 6 Subventricular zone neural progenitor mobilization is increased by oral administration of VCE-003.2. Mice were analyzed 4 weeks after
lesion induced by AAV-htt16Q and AAV-htt94Q bilateral injection and daily treatment with vehicle or VCE-003.2 (10 mg/kg). Confocal microscopy
characterization of the SVZ was performed with Ascl1-specific antibody in the indicated experimental groups. Quantification of transit amplifying
progenitors labelled with Ascl1. AAV-htt-16Q (Vehicle and VCE-003.2, n = 5 each) and AAV-htt94Q (Vehicle and VCE-003.2, n = 5 each). Statistics:
One-way ANOVA. F = 10.12; R2 = 0.65. ##p < 0.01; q = 4.25 AAV-htt94Q VCE-003.2 vs. AAV-htt94Q Veh and **p < 0.01; q = 7.12 AAV-htt94Q VCE-
003.2 vs. AAV-htt16Q Veh. Scale bar, 100 μm
Aguareles et al. Translational Neurodegeneration             (2019) 8:9 Page 10 of 15undesired side-effects constitutes an attractive strategy
to solve these limitations.
PPARγ receptors are required for appropriate neurogen-
esis as it controls neural progenitor cell proliferation and
differentiation [25]. Noteworthy, the positive effect of
PPARγ in neurogenesis, requires fine-tune regulation, as
either its ablation or overactivation may hamper neuronal
differentiation [26]. Under pathological conditions, for in-
stance under an inflammatory insult, PPARγ activation
can restore neurogenesis and cognitive impairment [27].
Similarly, PPARγ activation can restore neurogenesis in
the OH-DA model of Parkinson’s disease [28] and prevent
amyloid-beta-induced cell death of human neural stem
cells [29]. In HD models, the administration of PPARγ ag-
onists protects from striatal neurodegeneration, attenuates
neuroinflammation and decreases oxidative damage
[30–32], supporting PPARγ as a valid target for the
management of HD.
CBD is the most widely investigated phytocannabinoid
devoid of psychotomimetic actions, and whereas its pre-
cise molecular mechanism of action remains the subject
of research, some CBD actions, including its protective ef-
fect in counteracting amyloid-induced inflammation and
neurogenesis deficits, are mediated by PPARγ receptors
[33]. Hence, CBD administration can restore hippocampalneurogenesis deficits induced by different nervous system
insults such as amyloid-beta pathology, chronic unpredict-
able stress and aging [34]. Other plant-derived cannabi-
noids such as CBG and tetrahydrocannabinolic acid
regulate PPARγ activity [15, 35] and, hence, constitute in-
teresting template structures for the development of new
molecules with improved selectivity, reduced side-effects
and better pharmacokinetic profile. Different strategies
have been applied to improve CBD pharmacological prop-
erties. Fluorinated derivatives or quinone modifications
have successfully generated new cannabinoid molecules
with better translational perspectives (e.g., HUF-101,
VCE-004). Thus, HUF-101 possesses improved anxiolytic,
antidepressant and antipsychotic properties compared to
the original CBD molecule [36]. Regarding CBG, its ami-
noquinone derivative VCE-003.2 has demonstrated effi-
cacy as a neuroprotective molecule in HD [14],
Parkinson’s disease [21] and amyotrophic lateral sclerosis
models [37]. Noteworthy, the VCE-003.2 compound is de-
void of the side effects seen with full PPARγ-agonists and,
hence, does not interfere with osteoblast differentiation
and is less adipogenic [14].
Cell replacement therapy has demonstrated efficacy in
HD experimental models and in preliminary studies in
patients [38]. Exogenous cell grafts of either fetal tissue
a b
Fig. 7 Oral administration of VCE-003.2 exerts a pro-neurogenic action. Mice were analyzed 4 weeks after lesion induced by AAV-htt16Q and AAV-
htt94Q bilateral injection and administered daily with vehicle or VCE-003.2 (10mg/kg). a Confocal microscopy characterization of migrating neuroblasts
identified with doublecortin antibody and quantification in the striatum of the indicated mice groups. b Effective neurogenesis was determined by
quantification of double positive cells labelled with BrdU and NeuN antibodies. AAV-htt16Q Vehicle and VCE-003.2 (n = 7 and 5, respectively); AAV-htt94Q
Vehicle and VCE-003.2 (n= 9 and 11, respectively). Statistics: One-way ANOVA. a F = 14.43; R2 = 0.69. ##p < 0.01; q = 6.95 AAV-htt94Q VCE-003.2 vs. AAV-
htt94Q Veh and **p < 0.01; q = 7.59 AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. b F = 13.99; R2 = 0.59. ##p < 0.01; q = 6.50 AAV-htt94Q VCE-003.2 vs. AAV-
htt94Q Veh and **p < 0.01; q = 7.59 AAV-htt94Q VCE-003.2 vs. AAV-htt16Q Veh. Scale bar, 100 μm
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atum, as well as integrate and ameliorate motor symptoms
and survival, however they face various challenges that
impede their development for disease-modifying strategy.
Considering that in HD postmortem tissue an increasedSVZ cell proliferation and neurogenesis is evident [39],
promoting endogenous SVZ-derived striatal neurogenesis
constitutes an alternative approach of interest. Promoting
SVZ neurogenesis by gene therapy-mediated delivery of
BDNF and noggin successfully delayed progression of the
Aguareles et al. Translational Neurodegeneration             (2019) 8:9 Page 12 of 15disease in the R6/2 mouse model [40, 41], and the same
approach induced neurogenesis in adult squirrel monkeys
[40]. These findings evidence that, even if endogenous
newly-born neurons express mutant huntingtin, neuro-
genesis is effective and able to counteract, at least in part,
neurodegeneration-evoked symptoms. In this scenario,
pharmacological promotion of adult neurogenesis by can-
nabinoids [42, 43] may constitute a plausible alternative to
gene therapy. In addition, cannabinoids could be used to
promote ES-derived striatal neurogenesis ex vivo for
mechanistic studies or cell replacement therapies.
In summary, our findings demonstrate that oral ad-
ministration of VCE-003.2 exerts a neuroprotective ac-
tion in a striatal neurodegeneration model that is
accompanied by an improved endogenous neurogenic
response. The capability of VCE-003.2 to increase effect-
ive neurogenesis suggests that this CBG derivative may
possess the ability to act as a disease-modifying drug ra-
ther than only a symptomatic reliever.
Conclusions
Oral administration of the cannabigerol derivative
VCE-003.2 is neuroprotective and improves subventri-
cular zone-derived neurogenesis in response to mu-
tant huntingtin-induced neurodegeneration. These
findings are relevant in the search for novel thera-
peutic strategies against Huntington’s disease progres-
sion, considering the lack of undesired side actions of
this novel cannabinoid-derived molecule and good
bioavailability upon oral administration.
Additional files
Additional file 1: Microsomal Metabolic Stability. Pooled human liver
microsomes (final protein concentration 0.5 mg/mL), 0.1 M phosphate
buffer pH 7.4 and the test compounds (VCE-003.2, CBG, verapamil and
dextromethorphan) were pre-incubated at 37 °C prior to the addition of
1 mM NADPH to initiate the reaction. The final incubation volume was
25 μL. Each compound was incubated for 0, 5, 15, 30 and 45 min. The
control (minus NADPH) was incubated for 45 min only. The reactions
were stopped by the addition of 50 μL methanol containing internal
standard at the appropriate time points. The incubation plates were
centrifuged at 2500 rpm for 20 min at 4 °C to precipitate the protein.
Following protein precipitation, the sample supernatants were analyzed
using LC-MS/MS. From a plot of ln peak area ratio (compound peak area/
internal standard peak area) against time, the gradient of the line was
determined. Subsequently, half-life and intrinsic clearance was calculated
using the equations below: Elimination rate constant (k) = (− gradient).
Half-life (t1/2) (min) = 0:693k . Intrinsic Clearance (CLint) (μL/min/mg protein)
= V0:693t1=2 . where V=Incubation volume mL/mg microsomal protein.
(PDF 373 kb)
Additional file 2: Cytochrome P450 Inhibition (IC50 Determination).
CYP1A Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final
DMSO concentration = 0.3%) was incubated with human liver microsomes
(0.25mg/mL) and NADPH (1mM) in the presence of the probe substrate
ethoxyresorufin (0.5 μM) for 5 min at 37 °C. The selective CYP1A inhibitor,
alpha-naphthoflavone, was screened alongside the test compounds as a
positive control. CYP2B6 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human livermicrosomes (0.1mg/mL) and NADPH (1mM) in the presence of the probe
substrate bupropion (110 μM) for 5 min at 37 °C. The selective CYP2B6
inhibitor, ticlopidine, was screened alongside the test compounds as a
positive control. CYP2C8 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.25mg/mL) and NADPH (1mM) in the presence of the probe
substrate paclitaxel (7.5 μM) for 30min at 37 °C. The selective CYP2C8
inhibitor, montelukast, was screened alongside the test compounds as a
positive control. CYP2C9 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (1mg/mL) and NADPH (1mM) in the presence of the probe
substrate tolbutamide (120 μM) for 60min at 37 °C. The selective CYP2C9
inhibitor, sulphaphenazole, was screened alongside the test compounds as
a positive control. CYP2C19 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM
in DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate mephenytoin (25 μM) for 60min at 37 °C. The selective CYP2C19
inhibitor, tranylcypromine, was screened alongside the test compounds as a
positive control. CYP2D6 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate dextromethorphan (5 μM) for 5 min at 37 °C. The selective CYP2D6
inhibitor, quinidine, was screened alongside the test compounds as a
positive control. CYP3A4 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.1mg/mL) and NADPH (1mM) in the presence of the probe
substrate midazolam (2.5 μM) for 5 min at 37 °C. The selective CYP3A4
inhibitor, ketoconazole, was screened alongside the test compounds as a
positive control. CYP3A4 Inhibition. VCE-003.2 (0.1, 0.25, 1, 2.5, 10, 25 μM in
DMSO; final DMSO concentration = 0.3%) was incubated with human liver
microsomes (0.5mg/mL) and NADPH (1mM) in the presence of the probe
substrate testosterone (50 μM) for 5 min at 37 °C. The selective CYP3A4
inhibitor, ketoconazole, was screened alongside the test compounds as a
positive control. For the CYP1A incubations, the reactions were terminated
by methanol, and the formation of the metabolite, resorufin, was monitored
by fluorescence (excitation wavelength = 535 nm, emission wavelength =
595 nm). For the CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 incuba-
tions, the reactions were terminated by methanol. The samples were
centrifuged, and the supernatants combined for the simultaneous analysis
of 4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, and 1-
hydroxymidazolam by LC-MS/MS. Hydroxybupropion, 6α-hydroxypaclitaxel
and 6ß-hydroxytestosterone were analyzed separately by LC-MS/MS. A
decrease in the formation of the metabolites compared to vehicle control
was used to calculate IC50 values. (PDF 323 kb)
Additional file 3: hERG Channel Inhibition (IC50 Determination). The
experiments were performed on an IonWorks™ HT instrument (Molecular
Devices Corporation), which automatically performs electrophysiology
measurements in 48 single cells simultaneously in a specialized 384-well
plate (PatchPlate™). The cells used were Chinese hamster ovary (CHO)
cells stably transfected with hERG (cell-line obtained from Cytomyx, UK).
A single-cell suspension was prepared in extracellular solution (Dulbecco’s
phosphate buffered saline with calcium and magnesium pH 7–7.2) and
aliquots added to each well of a PatchPlate™. Cells were positioned over
a small hole at the bottom of each well by applying a vacuum beneath
the plate to form an electrical seal. The resistance of each seal was
measured via a common ground-electrode in the intracellular
compartment and individual electrodes placed into each of the upper
wells. Electrical access to the cell was achieved by circulating a
perforating agent, amphotericin, underneath the PatchPlate™ and then
measuring the pre-compound hERG current. An electrode is positioned
in the extracellular compartment and a holding potential of − 80 mV
applied for 15 s. The hERG channels were then activated by applying a
depolarizing step to + 40 mV for 5 s and then clamped at − 50 mV for 4 s
to elicit the hERG tail current, before returning to − 80 mV for 0.3 s. VCE-
003.2 were added to the upper wells of the PatchPlate™. Solutions were
prepared by diluting 10 mM DMSO solutions of the test compound into
extracellular buffer such that the final concentrations tested are 0.008,
0.04, 0.2, 1, 5 and 25 μM (final DMSO concentration 0.25%). Quinidine, an
established hERG inhibitor, was included as a positive control and buffer
containing 0.25% DMSO was included as a negative control. Post-
Aguareles et al. Translational Neurodegeneration             (2019) 8:9 Page 13 of 15compound currents were then expressed as a percentage of pre-
compound currents and plotted against concentration for each
compound. Where concentration-dependent inhibition is observed, the
data are fitted and IC50 values were calculated. (PDF 322 kb)
Additional file 4: AMES Data Summary. AMES Experimental Procedure.
Approximately ten million bacteria are exposed in triplicate to VCE-003-.2
(7.8, 15.6, 31.3, 62.5, 125 and 250 μg/ml), a negative control (vehicle) and
a positive control for 90 min in medium containing a low concentration
of histidine (sufficient for about 2 doublings). The cultures were then
diluted into indicator medium lacking histidine and dispensed into 48
wells of a 384 well plate (micro-plate format, MPF). The plate was
incubated for 48 h at 37 °C, and the number of wells showing growth
were counted and compared to the vehicle control. An increase in the
number of colonies of at least two-fold over baseline (mean + SD of the
vehicle control) and a dose response indicates a positive response. An
unpaired, one-sided Student’s T-test was used to identify conditions that
are significantly different from the vehicle control. Where indicated, S9
fraction from the livers of Aroclor 1254-treated rats was included in the
incubation at a final concentration of 4.5%. An NADPH-regenerating
system is also included to ensure a steady supply of reducing equivalents.
The strains used in this study were S. typhimurium TA98 (hisD3052, rfa,
uvrB/pKM10 for detection of frame-shift mutations) and S. typhimurium
TA100 (hisG45, rfa, uvrB/pKM101 for detection of base-pair substitutions).
VCE-003.2 was assessed for its mutagenic potential in the AMES reverse
mutation assay. This test was performed in the absence and presence of S9
metabolic activation. VCE-003.2 was found to be negative for genotoxicity
in this AMES study. The positive controls all behaved as expected.
(PDF 568 kb)
Additional file 5: Effect of oral VCE-003.2 on plasmatic biomarkers.
Plasma samples from the indicated groups of animals (n = 6) were pooled
and subjected to mouse cytokine array (ARY028; R&D Systems) and
mouse adipokine array (ARY013; R&D Systems) analysis. The relative
expression of the indicated biomarkers is shown. (PDF 338 kb)
Additional file 6: 3-Nitroproprionic acid model of striatal
neurodegeneration. 16-week- old C57BL/6 N male mice (Harlan Ibérica,
Barcelona, Spain) were subjected to seven intraperitoneal (i.p.) injections
of 50 mg/kg 3-NP (one injection each every 12 h prepared in phosphate-
buffered saline (PBS)]. 3-NP-treated animals and their respective non-
lesioned controls (injected with PBS) were used for pharmacological
studies with VCE-003.2. Treatments consisted of oral gavage every 24 h
with VCE-003.2 at a dose of 10 mg/kg using sesame oil as vehicle. 12 h
after the last injection of 3-NP motor activity, hindlimb clasping and
kyphosis were evaluated as previously described [12]. Animals were
euthanized at the indicated time after huntingtin-AAV infection or 12 h
after the last injection of 3NP and their brains removed. Statistical
analysis: One-way ANOVA followed by the Tuckey’s post hoc test was
used to determine the statistical significance. All the in vivo data were
expressed as mean ± SEM. Kruskal-Wallis test was used to determine the
statistical in the case of non-parametric analysis. a) Hindlimb Clasping
(F = 8.069; p = 0.0047) post hoc test: p = 0.0036 3NP vs Veh; Locomotor
activity (F = 18.62; p = 0.0001) post hoc test p < 0.0001 3NP vs Veh, p =
0.0027 3NP + VCE-003.2 vs 3NP; Kyphosis (F = 28.24 p < 0.0001) post hoc
test: p < 0.0001 3NP vs Veh, p < 0.0001 3NP + VCE-003.2 vs 3NP. b) TNF-α
(F = 18.17 p = 0.0028) post hoc test: p = 0.0027 3NP vs Veh, p = 0.0138
3NP + VCE-003.2 vs 3NP. IL-6 (Kruskal-Wallis statistic = 6.880 p = 0.0071)
post hoc test: p = 0.0265 3NP vs Veh. c) Average number of neurons per
field (F = 15.69 p = 0.0012) post hoc test: p = 0.0011 3NP vs Veh, p = 0.0086
3NP + VCE-003.2 vs 3NP; Number of Iba1+ cells (F = 10.82 p = 0.0040) post
hoc test: p = 0.0101 3NP vs Veh, p = 0.0059 3NP + VCE-003.2 vs 3NP.
(PDF 325 kb)
Abbreviations
AAV: Adeno associated virus; CBG: Cannabigerol; HD: Huntington’s disease;
Htt: Huntingtin; MSN: Medium spiny neuron; PPAR: Peroxisome proliferator-
activated receptor; SVZ: Subventricular zone
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